France's Poxel Q3 revenue rises on higher TWYMEEG royalties

By Reuters News


Overview

  • France biopharma reported Q3 2026 revenue up 51% yr/yr, driven by TWYMEEG royalties

  • TWYMEEG net sales in Japan rose 29% yr/yr, triggering higher royalty rate for Poxel

  • Company generated positive net royalties for the first time as royalty rate increased to 10%


Outlook

  • Sumitomo Pharma expects TWYMEEG net sales to exceed JPY 10 bln in FY 2026

  • Upon JPY 10 bln sales milestone, Poxel to receive JPY 1 bln payment from Sumitomo Pharma


Result Drivers

  • TWYMEEG SALES GROWTH - Co said 29% yr/yr increase in TWYMEEG net sales in Japan drove higher royalties

  • ROYALTY RATE INCREASE - Royalty rate on TWYMEEG sales rose from 8% to 10% after sales exceeded JPY 5 bln threshold

  • RETROACTIVE ROYALTY ADJUSTMENT - Q3 revenue included retroactive adjustment to royalties for prior quarter


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 1.95 mln


Reuters Recommended Reads

  • Oct 16 - Diagnostics firm Biomerica's Q1 revenue drops on lower clinical lab orders


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.